BioMark: 2025 Achievements & 2026 Vision
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux. Dear BioMark Shareholders and Team, As we reflect on 2025, we celebrate a transformative year that positions B
Technology, Biotechnology, Healthcare and Hospitals
2025-12-31 8:30 AM EST | BioMark Diagnostics, Inc.
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company's Annual General Meeting (AGM) held on December 22nd, 2025. Mr. Lavender and his group we
Technology, Biotechnology, Healthcare and Hospitals
2025-12-30 8:30 AM EST | BioMark Diagnostics, Inc.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-23 4:40 PM EST | Theralase Technologies Inc.
A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors
Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to philanthropic leadership and international recognition, 2025 has marked a defining year for Dr. Christina Rahm. As Chief Science Officer of The ROOT Brands and founder of DRC Ventures, Dr. Rahm continues to lead at the intersection of science, sustainability and purpose-driven innovation. Her work this year has expanded far beyond the laboratory, spanning continents, empowering commu
Biotechnology, Food / Beverages, Health
2025-12-23 11:41 AM EST | DRC Ventures
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025. BioMark has engaged the Standards
Technology, Biotechnology, Healthcare and Hospitals
2025-12-23 8:30 AM EST | BioMark Diagnostics, Inc.
Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan. The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for
Technology, Biotechnology, Health
2025-12-22 12:00 PM EST | Restart Life Sciences Corp.
Entheon Announces Letter of Intent with Nutravisor Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding Letter of Intent (the "LOI") dated December 18, 2025, with Nutravisor Inc. ("Nutravisor") whereby Entheon will acquire all of the issued and outstanding common shares of Nutravisor (the "Proposed Transaction"). Upon completion of the Proposed T
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2025-12-22 9:30 AM EST | Entheon Biomedical Corp.
Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart" or the "Company") is pleased to announce that it has signed a binding letter of intent dated December 21st, 2025 (the "LOI"), which sets out the proposed terms by which the Company would acquire 100% of the shares of Holy Crap Foods Inc. ("Holy Crap"), from Happy Belly Food Group Inc. (CSE: HBFG) (the "Ac
Technology, Biotechnology, Health
2025-12-22 8:00 AM EST | Restart Life Sciences Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering") previously announced on October 14, 2025 has been updated. The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share
2025-12-19 5:05 PM EST | Sharp Therapeutics Corp.
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with the University of Athens. This retrospective study is a key component of Telo's expanding, multi-center MRD validation program and is designed
2025-12-18 4:05 PM EST | Telo Genomics Corp.
Maxwell Biosciences Subsidiary Havih Announces Partnership with the Government of Andhra Pradesh
Austin, Texas--(Newsfile Corp. - December 18, 2025) - Maxwell Biosciences subsidiary, Havih Envirosciences, an Indian citizen-owned and operated life sciences company, announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state. The collaboration was formalized through an agreement with the Andhra Pradesh Centre for Advanced Research on Livestock Limited (APCARL) on November 21, 2025.
Biotechnology, Pharmaceuticals
2025-12-18 9:00 AM EST | Maxwell Biosciences, Inc.
Restart Life Closes Over-Subscribed Second Tranche Financing
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025 and December 5, 2025, the Company has closed the over-subscribed second tranche of its non-brokered private placement for total gross proceeds of CDN$630,000 (the "Placement"). As announced on November 12, 2025, the company intended to raise a total of up t
Technology, Biotechnology, Health
2025-12-18 8:00 AM EST | Restart Life Sciences Corp.
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the study's full enrollment target. Despite holiday scheduling and year-end operating room
Biotechnology, Healthcare and Hospitals
2025-12-18 8:00 AM EST | Envoy Medical, Inc.
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence
Biotechnology, Pharmaceuticals, Health
2025-12-18 7:30 AM EST | BioHarvest Sciences Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.